Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity

Published: 29 September 2021
Abstract Views: 473
PDF: 265
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

New disruptors of the ERCC1-XPF interaction interaction have a synergistic effect with traditional NER inhibitors, in p53 positive cells. Furthermore, the synergy can be resumed in p53 negative cells upon reactivation of the TP53 gene.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

[1] Gentile, F, Elmenoufy, AH, Ciniero, G, et al. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein–protein interaction. Chem Biol Drug Des 2020;95:460– 71.
[2] Jordheim LP, Barakat KH, Heinrich-Balard L, et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol 2013;84:12-24.
[3] Friboulet L, Soria JC, Olaussen KA. The “Guardian of the Genome”—An Old Key to Unlock the ERCC1 Issue. Clin Cancer Res 2019;25:2369-71.
[4] Ciniero G, Elmenoufy AH, Gentile F, et al. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair. Cancer Chemother Pharmacol 2021;87:259-67.

How to Cite

Ciniero, G., Gentile, F., Elmenoufy, A. H., Cros-Perrial, E. ., West, F. G., Weinfeld, M., … Tuszynski, J. A. (2021). Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity. Biomedical Science and Engineering, 2(1). https://doi.org/10.4081/bse.164